Want to see IVF full AI Analyst Report?
Top Page
INVO Fertility
(NASDAQ:IVF)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.90
▼(-9.70% Downside)
Action:Reiterated
Date:07/11/26
The score is primarily held down by weak financial performance—large losses and ongoing cash burn—alongside bearish technical signals with the stock trading below major moving averages. Corporate events provide a modest offset via regained Nasdaq compliance and increased control of a clinic, but valuation support is limited given negative earnings and no stated dividend.
Positive Factors
Rapid revenue growth
Very strong TTM revenue growth off a small base demonstrates durable demand expansion for INVO's fertility services and INVOcell approach. Sustained top-line momentum can support scale advantages, broader clinic adoption and incremental investment returns if growth continues.
Negative Factors
Persistent negative cash flow
Sustained negative operating and free cash flow signals ongoing cash burn and reliance on external funding. Over several months this limits the company's ability to self-fund clinic expansion, absorb setbacks, or invest in R&D, raising medium-term solvency and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid revenue growth
Very strong TTM revenue growth off a small base demonstrates durable demand expansion for INVO's fertility services and INVOcell approach. Sustained top-line momentum can support scale advantages, broader clinic adoption and incremental investment returns if growth continues.
Read all positive factors
INVO Fertility (IVF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.21M
Dividend YieldN/A
Average Volume (3M)8.28M
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth9.50%
EPS Growth90.44%
CountryUS
Employees42
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-25.17
Shares Outstanding2,349,035
10 Day Avg. Volume24,408,967
30 Day Avg. Volume8,279,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.06
Price to Sales (P/S)0.06
P/FCF Ratio-0.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$10.42M
INVO Fertility Business Overview & Revenue Model
Company Description
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was establi...
How the Company Makes Money
null...
INVO Fertility Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.84M | 6.53M | 3.02M | 822.20K | 4.16M |
| Gross Profit | 2.53M | 2.87M | 1.09M | -28.57K | 4.02M |
| EBITDA | -3.51M | -7.14M | -6.88M | -10.75M | -5.22M |
| Net Income | -23.32M | -9.10M | -8.03M | -10.89M | -6.65M |
Balance Sheet | |||||
| Total Assets | 20.22M | 46.45M | 18.51M | 3.71M | 10.47M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 741.40K | 232.42K | 90.14K | 5.68M |
| Total Debt | 3.40M | 9.90M | 6.30M | 2.27M | 2.12M |
| Total Liabilities | 13.00M | 33.70M | 17.61M | 4.69M | 3.16M |
| Stockholders Equity | 7.22M | 12.75M | 892.83K | -977.61K | 7.31M |
Cash Flow | |||||
| Free Cash Flow | -7.06M | -3.16M | -5.20M | -6.62M | -6.48M |
| Operating Cash Flow | -7.01M | -2.97M | -4.76M | -6.60M | -6.03M |
| Investing Cash Flow | -2.75M | 363.89K | -2.49M | -81.22K | -2.15M |
| Financing Cash Flow | 11.10M | 3.12M | 7.39M | 1.09M | 3.77M |
INVO Fertility Technical Analysis
Negative
1.00
Price Trends
1.39
Negative
1.93
Negative
6.37
Negative
Market Momentum
-0.16
Positive
35.75
Neutral
6.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.39, and below the 200-day MA of 6.37, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 35.75 is Neutral, neither overbought nor oversold. The STOCH value of 6.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.
INVO Fertility Risk Analysis
INVO Fertility disclosed 60 risk factors in its most recent earnings report. INVO Fertility reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
INVO Fertility Peers Comparison
UnderperformOutperform
Sector (51)
IVF
INVO Fertility
0.94
-74.26
-98.76%
NIVF
NewGenIvf Group
0.81
-423.99
-99.81%
INVO Fertility Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
INVO Fertility Expands Authorized Shares to Support Financing
Neutral
Jul 24, 2026
On January 23, 2026, INVO Fertility held its annual meeting of stockholders, where shareholders re-elected all five directors and ratified Withum Smith+Brown, PC as the company’s independent auditor for the 2026 fiscal year. Investors also a...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
INVO Fertility Gains Full Control of Alabama Clinic
Positive
Jun 25, 2026
On June 23, 2026, INVO Fertility’s subsidiary INVO Centers acquired 100% of the membership interests in HRCFG, its joint venture partner in the Birmingham, Alabama fertility clinic, for a total consideration of $175,001 structured with minim...
Business Operations and StrategyRegulatory Filings and Compliance
INVO Fertility Updates Investors With New Presentation
Neutral
Jun 16, 2026
On June 16, 2026, INVO Fertility posted a new investor presentation on its website ahead of its appearance at the Planet MicroCap Conference scheduled for June 17, 2026. The presentation outlines the company’s current and long-term operation...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.